Abstract
Despite the enormous therapeutic potential of immune checkpoint blockade (ICB), it benefits only a small subset of patients. Some chemotherapeutics can switch ‘immune-cold’ tumours to ‘immune-hot’ to synergize with ICB. However, safe and universal therapeutic platforms implementing such immune effects remain scarce. We demonstrate that sphingomyelin-derived camptothecin nanovesicles (camptothesomes) elicit potent granzyme-B- and perforin-mediated cytotoxic T lymphocyte (CTL) responses, potentiating PD-L1/PD-1 co-blockade to eradicate subcutaneous MC38 adenocarcinoma with developed memory immunity. In addition, camptothesomes improve the pharmacokinetics and lactone stability of camptothecin, avoid systemic toxicities, penetrate deeply into the tumour and outperform the antitumour efficacy of Onivyde. Camptothesome co-load the indoleamine 2,3-dioxygenase inhibitor indoximod into its interior using the lipid-bilayer-crossing capability of the immunogenic cell death inducer doxorubicin, eliminating clinically relevant advanced orthotopic CT26-Luc tumours and late-stage B16-F10-Luc2 melanoma, and achieving complete metastasis remission when combined with ICB and folate targeting. The sphingomyelin-derived nanotherapeutic platform and doxorubicin-enabled transmembrane transporting technology are generalizable to various therapeutics, paving the way for transformation of the cancer immunochemotherapy paradigm.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
The data supporting the findings of this study are available within the article and the Supplementary Information. All relevant data are available from the authors upon reasonable request.
References
Haslam, A. & Prasad, V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw. Open 2, e192535 (2019).
Catenacci, D. V. T., Hochster, H. & Klempner, S. J. Keeping checkpoint inhibitors in check. JAMA Netw. Open 2, e192546 (2019).
Overman, M. J., Ernstoff, M. S. & Morse, M. A. Where we stand with immunotherapy in colorectal cancer: deficient mismatch repair, proficient mismatch repair, and toxicity management. Am. Soc. Clin. Oncol. Educ. Book 38, 239–247 (2018).
Huyghe, N., Baldin, P. & Van den Eynde, M. Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours? Gastroenterol. Rep. 8, 11–24 (2020).
Galon, J. & Bruni, D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug Discov. 18, 197–218 (2019).
Song, W. et al. Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap. Nat. Commun. 9, 2237 (2018).
Paz-Ares, L. et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med. 379, 2040–2051 (2018).
Whiteside, T. L., Demaria, S., Rodriguez-Ruiz, M. E., Zarour, H. M. & Melero, I. Emerging opportunities and challenges in cancer immunotherapy. Clin. Cancer Res. 22, 1845–1855 (2016).
Ebert, P. J. R. et al. MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade. Immunity 44, 609–621 (2016).
Ribas, A. et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 170, 1109–1119.e10 (2017).
Chen, Y. F. et al. Host immune response to anti-cancer camptothecin conjugated cyclodextrin-based polymers. J. Biomed. Sci. 26, 85 (2019).
Lu, J. et al. The self-assembling camptothecin-tocopherol prodrug: an effective approach for formulating camptothecin. Biomaterials 62, 176–187 (2015).
Dosset, M. et al. PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer. Oncoimmunology 7, e1433981 (2018).
Prendergast, G. C. et al. Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunol. Immunother. 63, 721–735 (2014).
Hou, D. Y. et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res. 67, 792–801 (2007).
Lob, S., Konigsrainer, A., Rammensee, H. G., Opelz, G. & Terness, P. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat. Rev. Cancer 9, 445–452 (2009).
Phan, T. et al. Salmonella-mediated therapy targeting indoleamine 2,3-dioxygenase 1 (IDO) activates innate immunity and mitigates colorectal cancer growth. Cancer Gene. Ther. 27, 235–245 (2020).
Gomes, B. et al. Characterization of the selective indoleamine 2,3-dioxygenase-1 (IDO1) catalytic inhibitor EOS200271/PF-06840003 supports IDO1 as a critical resistance mechanism to PD-(L)1 blockade therapy. Mol. Cancer Ther. 17, 2530–2542 (2018).
Metz, R. et al. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: a novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology 1, 1460–1468 (2012).
Du, J. Z., Du, X. J., Mao, C. Q. & Wang, J. Tailor-made dual pH-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery. J. Am. Chem. Soc. 133, 17560–17563 (2011).
Muller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E. & Prendergast, G. C. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med. 11, 312–319 (2005).
Kroemer, G., Galluzzi, L., Kepp, O. & Zitvogel, L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31, 51–72 (2013).
Gamcsik, M. P., Kasibhatla, M. S., Teeter, S. D. & Colvin, O. M. Glutathione levels in human tumors. Biomarkers 17, 671–691 (2012).
Zhong, Y. J., Shao, L. H. & Li, Y. Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review). Int. J. Oncol. 42, 373–383 (2013).
Shaw, J. P. & Chou, I. N. Elevation of intracellular glutathione content associated with mitogenic stimulation of quiescent fibroblasts. J. Cell. Physiol. 129, 193–198 (1986).
Jessani, N., Liu, Y., Humphrey, M. & Cravatt, B. F. Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness. Proc. Natl Acad. Sci. USA 99, 10335–10340 (2002).
Bucher, G. Ester pyrolysis of carbonates: bis(benzene hydrate) carbonate as potential precursor for monomeric carbonic acid. Eur. J. Org. Chem. 2010, 1070–1075 (2010).
Bhattacharyya, J. et al. A paclitaxel-loaded recombinant polypeptide nanoparticle outperforms Abraxane in multiple murine cancer models. Nat. Commun. 6, 7939 (2015).
Gabizon, A., Tzemach, D., Mak, L., Bronstein, M. & Horowitz, A. T. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models. J. Drug Target 10, 539–548 (2002).
Soundararajan, A., Bao, A., Phillips, W. T., Perez, R. 3rd & Goins, B. A. [(186)Re]liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model. Nucl. Med. Biol. 36, 515–524 (2009).
Kalra, A. et al. Abstract 2065: Magnetic resonance imaging with an iron oxide nanoparticle demonstrates the preclinical feasibility of predicting intratumoral uptake and activity of MM-398, a nanoliposomal irinotecan (nal-IRI). Cancer Res. 74, 2065–2065 (2014).
Song, W. et al. Trapping of lipopolysaccharide to promote immunotherapy against colorectal cancer and attenuate liver metastasis. Adv. Mater. 30, e1805007 (2018).
Low, P. S., Henne, W. A. & Doorneweerd, D. D. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc. Chem. Res. 41, 120–129 (2008).
Lu, J. et al. Targeted delivery of doxorubicin by folic acid-decorated dual functional nanocarrier. Mol. Pharmaceutics 11, 4164–4178 (2014).
Zhang, Y., Davis, C., Ryan, J., Janney, C. & Pena, M. M. Development and characterization of a reliable mouse model of colorectal cancer metastasis to the liver. Clin. Exp. Metastasis 30, 903–918 (2013).
Lu, J. et al. Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression. Nat. Commun. 8, 1811 (2017).
Slotte, J. P. The importance of hydrogen bonding in sphingomyelin’s membrane interactions with co-lipids. Biochim. Biophys. Acta 1858, 304–310 (2016).
Narvekar, M., Xue, H. Y., Eoh, J. Y. & Wong, H. L. Nanocarrier for poorly water-soluble anticancer drugs—barriers of translation and solutions. AAPS PharmSciTech 15, 822–833 (2014).
Lu, J. et al. PEG-derivatized embelin as a nanomicellar carrier for delivery of paclitaxel to breast and prostate cancers. Biomaterials 34, 1591–1600 (2013).
Lu, J. et al. An improved d-alpha-tocopherol-based nanocarrier for targeted delivery of doxorubicin with reversal of multidrug resistance. J. Control. Release 196, 272–286 (2014).
Rao, Y. et al. Bouchardatine analogue alleviates non-alcoholic hepatic fatty liver disease/non-alcoholic steatohepatitis in high-fat fed mice by inhibiting ATP synthase activity. Br. J. Pharmacol. 176, 2877–2893 (2019).
Konstantopoulos, P. et al. Metabolic effects of Crocus sativus and protective action against non-alcoholic fatty liver disease in diabetic rats. Biomed. Rep. 6, 513–518 (2017).
Abdel-Salam, O. M. E., Nada, S. A., Salem, N. A., El-Shamarka, M. E.-S. & Omara, E. Effect of Cannabis sativa on oxidative stress and organ damage after systemic endotoxin administration in mice. Comp. Clin. Pathol. 23, 1069–1085 (2013).
Clemente-Casares, X. et al. Expanding antigen-specific regulatory networks to treat autoimmunity. Nature 530, 434–440 (2016).
Wang, W. et al. RIP1 kinase drives macrophage-mediated adaptive immune tolerance in pancreatic cancer. Cancer Cell 34, 757–774.e7 (2018).
Zhang, Y., Huo, M., Zhou, J. & Xie, S. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput. Meth. Prog. Bio. 99, 306–314 (2010).
Litzenburger, U. M. et al. Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. Oncotarget 5, 1038–1051 (2014).
Acknowledgements
This work was supported in part by a Startup Fund from the College of Pharmacy at the University of Arizona and two Seed Grants from the University of Arizona BIO5 Institute and the State of Arizona’s Technology and Research Initiative Fund (TRIF), and by National Institutes of Health (NIH) grants (NIEHS P30 ES006694, NCI P30 CA023074 and NCI R01 CA092596). We acknowledge Statistical Consulting at the University of Arizona Information Technology for their assistance with the statistical analysis; the use of mass spectrometry equipment in the Analytical and Biological Mass Spectrometry Core Facility at the University of Arizona BIO5 Institute; the University of Arizona Translational Bioimaging Resource Core for the Lago live animal imaging; the University of Arizona University Animal Care Pathology Services for the serum chemistry and haematological counts; the TACMASR of the UACC for the IHC and H&E staining, immunofluorescence and confocal laser scanning microscopy; and Arizona State University’s John Cowley Center for High Resolution Electron Microscopy (the specific instrumentation used was supported by the National Science Foundation (NSF), MRI grant NSF1531991) for the cryo-EM.
Author information
Authors and Affiliations
Contributions
J.L. conceived and supervised the project. J.L. and Z.W. designed the experiments, analysed the data and wrote the manuscript. Z.W. performed the experiments. N.L., J.C., K.T.L. and K.T.L. assisted in the prodrug synthesis, nanoparticle preparation, HPLC and in vivo animal studies. W.H. assisted with the PCR assay. A.J.S. provided clinical research insight into antitumour efficacy studies. All of the authors discussed the results and commented on the manuscript.
Corresponding author
Ethics declarations
Competing interests
J.L. has applied for patents related to this study. The other authors have no competing interests.
Additional information
Peer review information Nature Nanotechnology thanks the anonymous reviewers for their contribution to the peer review of this work.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Supplementary Information
Supplementary Materials, Methods, Figs. 1–35 and refs. 1–7.
Rights and permissions
About this article
Cite this article
Wang, Z., Little, N., Chen, J. et al. Immunogenic camptothesome nanovesicles comprising sphingomyelin-derived camptothecin bilayers for safe and synergistic cancer immunochemotherapy. Nat. Nanotechnol. 16, 1130–1140 (2021). https://doi.org/10.1038/s41565-021-00950-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41565-021-00950-z
This article is cited by
-
A method for predicting drugs that can boost the efficacy of immune checkpoint blockade
Nature Immunology (2024)
-
The effects of metabolism on the immune microenvironment in colorectal cancer
Cell Death Discovery (2024)
-
Cholesterol-modified sphingomyelin chimeric lipid bilayer for improved therapeutic delivery
Nature Communications (2024)
-
Fine-tuning the structure-tolerance-antitumor efficacy axis of prodrug nanoassemblies via branched aliphatic functionalization
Nano Research (2024)
-
Bioactive fatty acid analog-derived hybrid nanoparticles confer antibody-independent chemo-immunotherapy against carcinoma
Journal of Nanobiotechnology (2023)